How’s the anti Covid Reithera vaccine going?
The Roman company Reithera controlled by a Swiss company, communicating an update on the Phase 1 clinical study, announces that its vaccine candidate GRAd-COV2 COVID-19 is well tolerated and induces immune response in healthy subjects aged between 18 and 55 years old. All the details
Reithera, communicating an update on the Phase 1 clinical trial, announces that its vaccine candidate GRAd-COV2 COVID-19 is well tolerated and induces immune responses in healthy subjects between the ages of 18 and 55. Phase 1 progresses in individuals aged 65 to 85. The study is conducted by the biotech company of Castel Romano, in the province of Rome, in collaboration with the Lazzaro Spallanzani National Institute for Infectious Diseases of Rome, and has received funding from the Ministry of the University and the Lazio Region . The results of the study – the company reports – should allow the selection of the vaccine dose for further Phase 2 and 3 clinical trials.
Here are all the details
WHAT REITHERA'S NOTE SAYS ABOUT PHASE 1 OF THE ANTI COVID VACCINE
The study – we read – was designed and conducted in collaboration with the National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani of Rome, and received funding from the MIUR – Ministry of Education, University and Research – and by the Lazio Region.
THE TIMING
The company based in Castel Romano in the province of Rome, controlled by a Swiss company , stated that the trial is proceeding according to the schedule and that the administration of the vaccine and the initial evaluation on the first group of healthy volunteers aged between 18 and 55 years was completed positively.
THE PRELIMINARY RESULTS
Preliminary results regarding this group, which was divided into 3 sub-groups of 15 subjects each to evaluate different vaccine doses, showed that GRAd-COV2 was well tolerated and generated antibodies at all three doses tested that they bind to the virus spike protein in addition to specific T lymphocytes.
THE EXPERIMENTATION
The experimentation continues to investigate the responses to GRAd-COV2 in the three new sub-groups, composed of healthy subjects aged between 65 and 85 years. The results of the study should allow selection of the vaccine dose for further Phase 2 and 3 clinical trials.
REITHERA'S COMMENT
“We are making progress in Phase 1 testing of GRAd-COV2 and have completed the first part exactly as planned. The first results show that, in younger subjects, our vaccine candidate is well tolerated and is able to stimulate immune responses against SARS-CoV-2. This result has allowed us to move to the vaccination of older subjects ”, said the CEO of ReiThera, Antonella Folgori.
THE WORDS OF FOLGORI (REITHERA)
"The enrollment of older volunteers is progressing as planned and we plan to communicate the first results of the study together with the plan for wider international studies by the end of the year." Folgori added: “We are grateful to the partners with whom we collaborate in the realization of this study: the Lazzaro Spallanzani Institute in Rome with which the study was designed and the GB Rossi University Hospital in Verona. We are particularly grateful to the many volunteers who participated in the experiment. It is a great collaborative effort to achieve a common goal ".
THE REACTION OF PREGLIASCO
"The results of the Italian vaccine candidate against Covid-19 developed by ReiThera are very interesting: they justify today's communication and, moreover, the project uses a consolidated technology, which should give good results in the future, as the experimentation goes on", he the virologist of the University of Milan Fabrizio Pregliasco said to Adnkronos Salute , commenting on the update on the Phase 1 clinical study.
START MAGAZINE INSIGHTS ON REITHERA:
WHO ARE THE SHAREHOLDERS AND FINANCERS OF THE REITHERA COMPANY
THE LAZIO REGION DOES NOT KNOW THAT REITHERA IS CONTROLLED BY A SWISS COMPANY
REITHERA AND IRBM, HERE'S THE ROLE OF ITALIANS IN ANTI COVID VACCINES
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/come-va-il-vaccino-di-reithera-anti-covid/ on Tue, 24 Nov 2020 11:13:30 +0000.